Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/28662 |
Resumo: | Objective: To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL. Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance. |
id |
UNIFEI_16424e4666bcef2ca893868d8c500a40 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/28662 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort studyPerfil lipídico en personas que inician la terapia antirretroviral con regímenes basados en efavirenz o dolutegravir en un centro de referencia en Brasil: un estudio de cohortePerfil lipídico em pessoas iniciando a terapia antirretroviral com regimes baseados em efavirenz ou dolutegravir em um centro de referência no Brasil: um estudo de coorteDislipidemiaTerapia Antirretroviral de Alta AtividadeInibidores de Integrase de HIVInibidores da Transcriptase Reversa.DislipidemiaTerapia Antirretroviral Altamente ActivaInhibidores de Integrasa VIHInhibidores de la Transcriptasa Inversa.DyslipidemiaAntiretroviral Therapy, Highly ActiveHIV Integrase InhibitorsReverse Transcriptase Inhibitors.Objective: To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL. Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance. Objetivo: Comparar el impacto sobre el perfil lipídico (PL) en personas que inician la terapia antirretroviral (TARV) con regímenes basados antes y después del uso de efavirenz (EFZ) o dolutegravir (DTG). Métodos: Cohorte prospectiva en la que se estratificaron dos grupos, personas que viven con el VIH (PVVS) que iniciaron el esquema con DTG o EFV. La dislipidemia se definió por criterios de laboratorio en el periodo comprendido entre septiembre de 2015 y octubre de 2017. Se utilizaron pruebas paramétricas y no paramétricas y pruebas de pares emparejados, considerando p <0,05 estadísticamente significativa. Resultados: se estudiaron 468 individuos estratificados en dos grupos, con (n=180) o sin (n=288) registros de pruebas de laboratorio en el momento T0 (inicio del tratamiento) o en el T48 (12 meses después de la dispensación de los antirretrovirales. De estos 180, 60 (33,1%) estaban en DTG y 113 (62,4%) en EFZ. En las comparaciones del nivel sérico (mg/dl) de PL, antes y después de la terapia antirretroviral, todos los valores mostraron un aumento y fueron estadísticamente significativos para el HDL (p<0,001). Se analizó la variación de la PL, post TARV y en relación con el uso de EFV y DTG. En cuanto a la EFZ, se produjo un aumento del nivel sérico de todo el PL, estadísticamente significativo para el HDL. En cuanto a la DTG, sólo se produjo un aumento del nivel sérico de VLDL que no fue estadísticamente significativo. Conclusión: Comparando el uso de DTG con EFV, EFV aumentó el nivel sérico de TC y fracciones, siendo estadísticamente significativo para HDL. Con el uso de DTG, hubo un aumento del nivel sérico de VLDL y una disminución de HDL, sin significación estadística.Objetivo: Comparar o impacto no perfil lipídico (PL) em pessoas iniciando a terapia antirretroviral (TARV) baseados pré e pós uso de efavirenz (EFZ) ou dolutegravir (DTG). Métodos: Coorte prospectiva onde foi estratificados dois grupos, as pessoas vivendo com HIV (PVIV) que iniciaram esquema com DTG ou EFV. A dislipidemia foi definida por critérios laboratoriais no período entre setembro de 2015 a outubro de 2017. Utilizados testes paramétrico e não paramétrico e testes de pares combinados, considerando o p <0,05 estatisticamente significativo. Resultados: estudados 468 indivíduos estratificados em dois grupos, com (n=180) ou sem (n=288) registros dos exames laboratoriais no tempo T0 (início do tratamento) ou no T48 (12 meses após a dispensação dos antirretrovirais. Entre esses 180, 60 (33,1%) estavam em uso de DTG e 113 (62,4%) em uso de EFZ. Nas comparações do nível sérico (mg/dl) do PL, pré e pós TARV, todos os valores apresentaram aumento e estaticamente significativo para o HDL (p<0,001). Foi analisado a variação do PL, pós TARV e em relação ao uso de EFV e DTG. Em relação ao EFZ, houve aumento do nível sérico de todo o PL, estaticamente significativo para o HDL. Em relação ao DTG, houve aumento do nível sérico apenas para o VLDL que não foi estaticamente significativo. Conclusão: comparando o uso do DTG com o EFV, o EFV aumentou o nível sérico do CT e frações, estaticamente significativa para o HDL. Com uso do DTG, houve um aumento do nível sérico de VLDL e diminuição do HDL, sem significância estatística.Research, Society and Development2022-04-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2866210.33448/rsd-v11i5.28662Research, Society and Development; Vol. 11 No. 5; e55811528662Research, Society and Development; Vol. 11 Núm. 5; e55811528662Research, Society and Development; v. 11 n. 5; e558115286622525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/28662/24846Copyright (c) 2022 Ana Cristina da Silva Fernandes; Jorgino Júlio Cesar; Palmira de Fátima Bonolo; Clessius Ribeiro de Souza; Maria das Graças Braga Ceccato https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFernandes, Ana Cristina da Silva Cesar, Jorgino Júlio Bonolo, Palmira de Fátima Souza, Clessius Ribeiro deCeccato , Maria das Graças Braga2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28662Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:59.264554Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study Perfil lipídico en personas que inician la terapia antirretroviral con regímenes basados en efavirenz o dolutegravir en un centro de referencia en Brasil: un estudio de cohorte Perfil lipídico em pessoas iniciando a terapia antirretroviral com regimes baseados em efavirenz ou dolutegravir em um centro de referência no Brasil: um estudo de coorte |
title |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
spellingShingle |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study Fernandes, Ana Cristina da Silva Dislipidemia Terapia Antirretroviral de Alta Atividade Inibidores de Integrase de HIV Inibidores da Transcriptase Reversa. Dislipidemia Terapia Antirretroviral Altamente Activa Inhibidores de Integrasa VIH Inhibidores de la Transcriptasa Inversa. Dyslipidemia Antiretroviral Therapy, Highly Active HIV Integrase Inhibitors Reverse Transcriptase Inhibitors. |
title_short |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
title_full |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
title_fullStr |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
title_full_unstemmed |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
title_sort |
Lipid profile in people starting antiretroviral therapy with efavirenz or dolutegravir based regimens from a reference center in Brazil: a cohort study |
author |
Fernandes, Ana Cristina da Silva |
author_facet |
Fernandes, Ana Cristina da Silva Cesar, Jorgino Júlio Bonolo, Palmira de Fátima Souza, Clessius Ribeiro de Ceccato , Maria das Graças Braga |
author_role |
author |
author2 |
Cesar, Jorgino Júlio Bonolo, Palmira de Fátima Souza, Clessius Ribeiro de Ceccato , Maria das Graças Braga |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Fernandes, Ana Cristina da Silva Cesar, Jorgino Júlio Bonolo, Palmira de Fátima Souza, Clessius Ribeiro de Ceccato , Maria das Graças Braga |
dc.subject.por.fl_str_mv |
Dislipidemia Terapia Antirretroviral de Alta Atividade Inibidores de Integrase de HIV Inibidores da Transcriptase Reversa. Dislipidemia Terapia Antirretroviral Altamente Activa Inhibidores de Integrasa VIH Inhibidores de la Transcriptasa Inversa. Dyslipidemia Antiretroviral Therapy, Highly Active HIV Integrase Inhibitors Reverse Transcriptase Inhibitors. |
topic |
Dislipidemia Terapia Antirretroviral de Alta Atividade Inibidores de Integrase de HIV Inibidores da Transcriptase Reversa. Dislipidemia Terapia Antirretroviral Altamente Activa Inhibidores de Integrasa VIH Inhibidores de la Transcriptasa Inversa. Dyslipidemia Antiretroviral Therapy, Highly Active HIV Integrase Inhibitors Reverse Transcriptase Inhibitors. |
description |
Objective: To compare the impact on lipid profile (LP) in people starting antiretroviral therapy (ART) before e after the use with efavirenz (EFZ) or dolutegravir (DTG) based regimens. Methods: A prospective cohort study stratified into two groups, the people living with HIV (PLWHIV) who started either DTG or EFV. Dyslipidemia was defined by laboratory criteria in the period from September 2015 to October 2017. Parametric and non-parametric tests and matched pair tests were used, considering p <0.05 statistically significant. Results: Studied 468 individuals stratified into two groups, with (n=180) or without (n=288) records of laboratory tests at time T0 (start of treatment) or at T48 (12 months after the dispensation of antiretroviral drugs. Among these 180, 60 (33.1%) were taking DTG and 113 (62.4%) were taking EFZ. In comparisons of serum PL level (mg/dl), pre and post ART, all values showed an increase and statically significant for HDL (p<0.001). The variation of PL was analyzed, post TARV and in relation to the use of EFV and DTG. In relation to EFZ, there was an increase in the serum level of the whole PL, statically significant for HDL. Regarding DTG, there was increase in serum level only for VLDL which was not statically significant. Conclusion: Comparing the use of DTG with EFV, EFV increased the serum level of TC and fractions, statically significant for HDL. With the use of DTG, there was an increase in serum VLDL level and decrease in HDL-C, without statistical significance. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04-15 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28662 10.33448/rsd-v11i5.28662 |
url |
https://rsdjournal.org/index.php/rsd/article/view/28662 |
identifier_str_mv |
10.33448/rsd-v11i5.28662 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/28662/24846 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 5; e55811528662 Research, Society and Development; Vol. 11 Núm. 5; e55811528662 Research, Society and Development; v. 11 n. 5; e55811528662 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052794641842176 |